ArrowArtboardCreated with Sketch.Title ChevronTitle ChevronEye IconIcon FacebookIcon LinkedinIcon Mail ContactPath LayerIcon MailMenu BurgerPositive ArrowIcon PrintIcon SearchSite TitleTitle ChevronIcon Twitter
Science

Kyoto University to start providing Embryonic Stem cells for clinical studies

The move, a first for Japan, will widen applications of regenerative medicine

KYOTO, Japan -- Kyoto University said Tuesday it will start providing human embryonic stem cells by July to colleges and private companies for clinical trials. The cells, like induced pluripotent stem cells, can create various types of organs and tissues.

The move is expected to help expand ES cell studies in the country, and lead to wider application of regenerative medicine.

Kyoto University has established an environment to produce ES cells from unused fertilized eggs from infertility treatments, and provide the cells to outside parties. The prominent university has already stockpiled iPS cells and provided them to universities and research institutions in Japan.

"ES cells are a new and promising option for regenerative medicine," said associate professor Hirofumi Suemori. "By making comparison with iPS cells, the use of ES cells will help in the development of safer and more effective options in regenerative medicine treatments."

Anyone who wants to use the ES cells has to apply to Kyoto University. A single cell costs 30,000 yen ($270) for colleges and 60,000 yen for private companies. Kyoto University has already received several inquiries. The ES cells it provides will be used for clinical trials.

In Japan, the use of ES cells, which are produced from human embryos, had been limited to basic research for ethical reasons. The government in 2014 changed its guidelines, making possible the use of the cells in clinical studies for disease treatments.

Sponsored Content

About Sponsored Content This content was commissioned by Nikkei's Global Business Bureau.

You have {{numberArticlesLeft}} free article{{numberArticlesLeft-plural}} left this monthThis is your last free article this month

Stay ahead with our exclusives on Asia;
the most dynamic market in the world.

Stay ahead with our exclusives on Asia

Get trusted insights from experts within Asia itself.

Get trusted insights from experts
within Asia itself.

Get Unlimited access

You have {{numberArticlesLeft}} free article{{numberArticlesLeft-plural}} left this month

This is your last free article this month

Stay ahead with our exclusives on Asia; the most
dynamic market in the world
.

Get trusted insights from experts
within Asia itself.

Try 3 months for $9

Offer ends April 19th

Your trial period has expired

You need a subscription to...

  • Read all stories with unlimited access
  • Use our mobile and tablet apps
See all offers and subscribe

Your full access to the Nikkei Asian Review has expired

You need a subscription to:

  • Read all stories with unlimited access
  • Use our mobile and tablet apps
See all offers
NAR on print phone, device, and tablet media